Dysregulation of the alternative complement pathway predisposes individuals to a number
of diseases. It can either be evoked by genetic alterations in or by stabilizing antibodies to …

Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases,
each commonly manifesting as a spectrum of symptoms, complications, and comorbidities …

The endocannabinoid system has been shown to be involved in various skin functions, such
as melanogenesis and the maintenance of redox balance in skin cells exposed to UV …

The treatment of psoriasis has been revolutionized by the emergence of biological
therapies. Monoclonal antibodies (mAb) generally have complex pharmacokinetic (PK) …

Juvenile generalized pustular psoriasis (GPP) is rare and often resistant to conventional
systemic therapy such as methotrexate, retinoic acid and cyclosporin A. GPP can be induced …

Objective To evaluate secukinumab (SEC) 300 mg and 150 mg vs placebo in a United
States–only population of biologic-naïve patients with psoriatic arthritis (PsA). Methods …

Background Secukinumab is effective against a range of psoriatic manifestations.
Investigating psoriasis (PsO) relapse following secukinumab discontinuation could provide …

Background and objective Anti‐IL‐17A IgG/κ monoclonal antibody CJM112 binds both IL‐
17A and IL‐17AF. The purpose of this First‐in‐Human study was to assess CJM112 effects …

Background Patients with severe autosomal recessive congenital ichthyosis (ARCI) show a
T helper 17/interleukin 17 (Th17/IL17) skewing in their skin and serum, resembling the …

Objective: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin-
17A, improved the signs and symptoms of ankylosing spondylitis (AS) in three Phase 3 …